IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer

Posted: December 10, 2021 at 1:55 am

NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its proprietary DeltEx platform, today announced the promotion of Kate Rochlin, Ph.D. to Chief Operating Officer (COO). Dr. Rochlin previously served as Vice President, Operations and Innovation.

See more here:
IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer

Related Posts